Dr. Azizad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
18433 Roscoe Blvd
Ste 208
Northridge, CA 91325Phone+1 818-341-4401Fax+1 818-341-4402
Summary
- Dr. Masoud Azizad is an internal medicine specialist based in Reseda, CA. He completed his Medical residency at Santa Barbara Cottage Hospital post his graduation from New York Medical College in 1999. His clinical skills and expertise extend to the management of hypertension, diabetes, and cerebrovascular disease. Dr. Azizad's research has been widely recognized and he has several publications to his name related to COVID-19 treatments and diabetes care which have been frequently cited. He has also contributed to various clinical trials, notably those concerning Alzheimer's disease and heart failure treatments. Further, he was honored with the CMS Meaningful Use Stage 1 Certification from athenaClinicals EHR, athenahealth, Inc in the years 2012-2013.
Education & Training
Santa Barbara Cottage HospitalResidency, Internal Medicine, 1999 - 2002
New York Medical CollegeClass of 1999
Certifications & Licensure
CA State Medical License 2001 - 2025
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification athenaClinicals EHR, athenahealth, Inc, 2012-2013
Clinical Trials
- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
- Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency Start of enrollment: 2017 Mar 15
- A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) Start of enrollment: 2021 Aug 27
Publications & Presentations
PubMed
- 17 citationsPlozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.Christie M Ballantyne, Szilard Vasas, Masoud Azizad, Peter Clifton, Robert S Rosenson
The New England Journal of Medicine. 2024-09-12 - 224 citationsA phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.William A Fischer 2nd, Joseph J Eron Jr, Wayne Holman, Myron S Cohen, Lei Fang
Science Translational Medicine. 2022-01-19 - 17 citationsA randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic...Michael Dougan, Masoud Azizad, Bharat Mocherla, Robert L. Gottlieb, Peter Chen
Clinical Infectious Diseases. 2021-10-28
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
